Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05954117 | Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia(CHIFMEOE) | not yet recruiting | N/A | 60 | University Hospital, Clermont-FerrandOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05354674 | Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis | not yet recruiting | — | 302 | Fudan UniversityOTHER | 1 | Jul 13, 2023 |
| clinicaltrials |
| NCT05940116 | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 322 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05941169 | Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy(PrimerX) | not yet recruiting | N/A | 750 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 0 | Jul 12, 2023 | clinicaltrials |
| NCT05934058 | Genomic and Dietary Aspects in Gastric Cancer Risk(GenoStoP) | not yet recruiting | — | 383,980 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05875649 | A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure(CLAG) | not yet recruiting | — | 137 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05931055 | The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer | not yet recruiting | — | 1,000 | Peking Union Medical College HospitalOTHER | 0 | Jul 5, 2023 | clinicaltrials |
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | not yet recruiting | Phase 2 | 22 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05840042 | Epidemiology and Risk Factors of Uterine Fibroids in China | not yet recruiting | — | 20,000 | Shixuan WangOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05909423 | Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer(FLU-IMMUNE) | not yet recruiting | Phase 2 | 21 | Zealand University HospitalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05909826 | Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM(KMM-KCd) | not yet recruiting | Phase 2 | 49 | Dong-A University HospitalOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05814848 | A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Phase 4 | 13 | Changhai HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05903703 | Canagliflozin With Gemcitabine in Pancreatic Carcinoma | not yet recruiting | N/A | 20 | Zhang Xiaofeng,MDOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05897138 | A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05901025 | Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients | not yet recruiting | — | 5,000 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05896956 | The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases | not yet recruiting | — | 500 | RenJi HospitalOTHER | 0 | Jun 9, 2023 | clinicaltrials |
| NCT05895214 | Mesopancreas Study in Pancreatic Cancer(MESOPANC-01) | not yet recruiting | — | 500 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05887505 | Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy | not yet recruiting | N/A | 120 | Taoyuan General HospitalOTHER_GOV | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05891080 | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial | not yet recruiting | Phase 2 | 124 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05881746 | Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness | not yet recruiting | N/A | 176 | Fudan UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05881057 | Application of SERS Technology Based Intraoperative Navigation System in Lung Cancer | not yet recruiting | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | May 30, 2023 | clinicaltrials |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | not yet recruiting | Phase 3 | 312 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 0 | May 26, 2023 | clinicaltrials |
| NCT04809792 | MR-Linac for Head and Neck SBRT | not yet recruiting | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 0 | May 23, 2023 | clinicaltrials |
| NCT05496166 | The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 348 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05841134 | Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer | not yet recruiting | Phase 2 | 25 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 9, 2023 | clinicaltrials |
| NCT05850559 | Assessment of the Diagnostic Role of Serum Insulin-like Growth Factor Binding Protein-3 as a Potential Biomarker for Colorectal Cancer (CRC) in Egypt | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | May 9, 2023 | clinicaltrials |
| NCT05842746 | Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma | not yet recruiting | Phase 2 | 74 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05841381 | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | not yet recruiting | Phase 3 | 876 | Fudan UniversityOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT05841849 | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | not yet recruiting | Phase 4 | 1,028 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05827471 | Clinical Study of QSOX1 as a Biomarker for Colon Cancer | not yet recruiting | — | 400 | Qianfoshan HospitalOTHER | 0 | Apr 25, 2023 | clinicaltrials |
| NCT05812235 | Bone Microstructure by Using HR-pQCT After Esophagectomy | not yet recruiting | — | 118 | Nagasaki UniversityOTHER | 0 | Apr 24, 2023 | clinicaltrials |
| NCT05822284 | ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy | not yet recruiting | — | 50 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05813665 | A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone | not yet recruiting | Phase 3 | 146 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT03969693 | Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation | not yet recruiting | — | 50 | Chang Gung Memorial HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05361954 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 36 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Apr 12, 2023 | clinicaltrials |
| NCT05806073 | Elective vs Therapeutic Neck Dissection in Treatment of Patients With Clinical T1/2N1M0 Oral Squamous Cell Carcinoma | not yet recruiting | N/A | 188 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Apr 12, 2023 | clinicaltrials |
| NCT05810623 | Single-Dose Intravesical Chemotherapy After Diagnostic URS(MINERVA) | not yet recruiting | Phase 3 | 394 | David D'AndreaOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05807984 | Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion | not yet recruiting | Phase 2 | 31 | Xin CaiOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 | clinicaltrials |
| NCT04788927 | Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study(PPGL-Pred) | not yet recruiting | — | 400 | Rigshospitalet, DenmarkOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05804864 | A Study of KM501 in Patients With Solid Tumors | not yet recruiting | Phase 1 | 96 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05794750 | Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）(AK104-IIT-13) | not yet recruiting | Phase 2 | 50 | JIN JINGOTHER | 0 | Apr 6, 2023 | clinicaltrials |
| NCT05767892 | YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | not yet recruiting | Phase 3 | 350 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05799469 | Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 36 | Chongqing University Cancer HospitalOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05784974 | Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer | not yet recruiting | Phase 2 | 37 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05779553 | Evaluation of Serum Tumor Endothelial Marker1 as a Potential Biomarker for Colorectal Cancer Diagnosis and Cancer Progression | not yet recruiting | — | 90 | Assiut UniversityOTHER | 0 | Mar 22, 2023 | clinicaltrials |
| NCT05780294 | A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC | not yet recruiting | Phase 3 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05778097 | Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)(ARES) | not yet recruiting | Phase 2 | 103 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05778149 | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 20, 2023source: clinicaltrials